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This review describes the adjuvanticity of novel diterpenoids (synthetic phytol derivatives)
compared to some commercially available adjuvants. The efﬁcacy of the phytol-derived
immunostimulants was evaluated in terms of their ability to activate innate immunity,
amplify various antigen-speciﬁc immune responses, and engender immunological mem-
ory with no discernible adverse effects in both competent and immune-deﬁcient mice.
The proﬁle that emerges out of these studies reveals that the phytol derivatives are
excellent immunostimulants, superior to a number of commercial adjuvants in terms of
long-term memory induction and activation of both innate and acquired immunity. Addi-
tionally, the phytol-derived compounds have no cumulative inﬂammatory or toxic effects
even in immuno-compromised mice.
Keywords: immunostimulants, phytol derivatives, isoprenoid adjuvants, activation of innate immunity, vaccine
efficacy, cytokine microenvironment, inflammasome, antibody and CTL response
“The art of healing comes from nature and not from the physician.
Therefore, the physician must start from nature with an open mind.”
-Paracelsus
Immunostimulants and immunomodulators abound in
nature. All through human history, vast arrays of natural com-
pounds, particularly those from plant and microbial sources, have
provided a wealth of immunomodulators. In many ways, they
help preserve all life forms and their relations, even in the midst
of adversities and mutual antagonisms. Despite being strangers
or dangerous, both commensals and harmful agents can unleash
modulators to enrich their hosts’ immune repertoire and bolster
the immune system (McKee et al., 2010;Norton et al., 2010). Mod-
ulators or immunoadjuvants from simple inorganic salts like alum
(Marrack et al., 2009) to bacterial cell wall constituents (Lederer,
1980; Strominger, 2007) have all been found to enhance vaccine
efﬁcacy. Chemical modiﬁcations and syntheses become neces-
sary to improve immunoadjuvants or modulators and to unravel
structure–function relationship (Azuma, 1992; Spanedda et al.,
2010). The fact that the immunogenicity of a substance depends
largely on the use of adjuvants was observed almost a century ago.
However, the underlying mechanism still deﬁes clarity, primarily
because of the empirical and diverse nature that surrounds the
selection and assessment of immunoadjuvants. No wonder, adju-
vants have come to be regarded as “immunologists’ dirty tricks”
(Janeway, 1989).
A group of compounds that has in recent years garnered lots
of interest in the ﬁeld of adjuvants, are terpenoids, speciﬁcally
lipophilic squalene, a triterpene (Benísek et al., 2004), and QS-
21, a hydrophilic triterpene glycoside (Soltysik et al., 1995; Kensil
and Kammer, 1998). Terpenoids or terpenes comprise the largest
and most diverse class of secondary metabolites (such as squalene
involved in cholesterol biosynthesis); approximately 55,000 com-
pounds have been identiﬁed to date (Maimone and Baran, 2007).
While the enzymes responsible for terpene synthesis are found
in all classes of microorganisms, plants, and animals, terpenes
and terpene-derived structures are most widely synthesized by
higher plants (Zwenger and Basu, 2008). All classes of terpenes
are synthesized from C5 isoprene units that have been linked
end-to-end. Monoterpenes (C10) and sesquiterpenes (C15) are
often ﬂavor and fragrance components of essential oils. In con-
trast, the carotenoids (C40) are yellow to red plant pigments,
while the photosynthetic green pigment chlorophyll is composed
of a magnesium-containing chlorin ring and a long side-chain
containing the acyclic diterpenoid, phytol (C20). Plant essential
oils, which are complex mixtures of volatile monoterpenes and
sesquiterpenes, protect plants from disease, infestation, and pre-
dation. These oils have also been shown to have antimicrobial,
anti-parasitic, insecticidal, and antioxidant/pro-oxidant activities
(Isman, 2006; Bakkali et al., 2008). Many plant terpenoids are
cytotoxic to tumor cells, making them useful chemotherapeutic
or chemopreventive compounds (Mo and Elson, 2004; Thoppil
and Bishayee, 2011). Paclitaxel (Taxol) and related taxanes are the
most well known anti-cancer agents. The anti-cancer activities
of some terpenoids are based on their ability to undergo protein
prenylation (Bifulco, 2005). Some plant terpenoids have activities
that make them useful research tools, for example in develop-
ing new drug delivery systems (Shieh et al., 1995; Kazanietz,
2005).
Based on their biological activities, terpenoids can be broadly
classiﬁed into three categories: cellular function,defense, and com-
munication. For example, terpenoids are involved in biosynthetic
pathways such as cholesterol, in defense as in toxins or repel-
lents, and in communications as hormones in aggressions and
alarm pheromones (Pickett and Gibson, 1983; Harrewijn et al.,
2001). Many natural isoprenoids like squalene and vitamin E are
known for their beneﬁcial effects on the immune system. A num-
ber of excellent reviews on squalene-based MF59 adjuvant have
appeared in recent years (Reddy and Couvreur, 2009; Kalvodova,
2010; Seubert et al., 2011). Squalene is also a constituent of com-
mercial adjuvants like Titermax, and Ribi’s adjuvant. From this
prospective, it is therefore quite understandable that many of these
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compounds from plant and animals have found wide usage in the
rational design of pharmaceuticals and immunological adjuvants.
However it is inconceivable that a single compound could ﬁt all
that is expected of a versatile immunomodulator/adjuvant. It is
critical to develop well-deﬁned, non-toxic adjuvants that would
function as cocktails and augment the immunogenicity of diverse
immunogens.
Epidemiological studies have suggested the importance of
green vegetables in diets in order to improve resistance to infection
and thus enhance immunity (Elson and Yu, 1994). Chlorophylls,
found in all green vegetables, constitute an important source
of an isoprenoid component, phytol (3, 7, 11, 15-tetramethyl-
2-hexadecen-1-ol, C20H40O). It is an acyclic monounsaturated
diterpene alcohol, present in vitamin K, vitamin E, and other toco-
pherols. Because phytol and other isoprenoids are lipophilic, they
are capable of interacting with cell membranes as well as other
lipophilic substances and metabolites (Glomset et al., 1990; Rilling
et al., 1990). This ability makes these compounds suitable for use
as immune adjuvants, the outcomes of which may lie in efﬁcient
delivery of antigens to antigen-presenting cells, up-regulation of
costimulatory molecules and promotion of cellular crosstalk. We
have been speciﬁcally interested in phytol since it is structurally
simple, easily available, and cost–effective. Additionally, it was rea-
soned that because of regular dietary intake, phytol should be well
tolerated by the body. These considerations led us to assess the
adjuvanticity of phytol and its synthetic derivatives in mice and
report their efﬁcacy in vaccine formulations (Lim et al., 2006a,b;
Aachoui et al., 2011a; Ghosh, 2012).
WHY USE PHYTOL DERIVATIVES AS ADJUVANTS?
Medium-length straight chain hydrocarbons (optimum 12 car-
bons) have previously been shown to be the most potent adjuvants
(Reeves et al., 2009). Mineral or hydrocarbon oils cause inﬂam-
mation and augment immune responsiveness. This ﬁnding led to
the use of mineral oil-in-water emulsions as immunoadjuvants for
several decades (Wilner et al., 1963). Complete Freund’s adjuvant
(CFA) that contains mycobacterial protein in addition to mineral
oil is one of the most potent adjuvants known. However, because
of its unfavorable risk/beneﬁt ratio, use of CFA in humans has
been prohibited (Satoh et al., 2003; Kuroda et al., 2004). On the
contrary, oil-in-water adjuvant, which was licensed for human use
in Europe almost a decade ago, is an isoprenoid, squalene-based
MF59. Although MF59 is safe, some of its components including
squalene were found to be arthritogenic in rodents (Holm et al.,
2004). This issue has raised questions about the safety of MF59 and
may restrict its use in vaccines in the future. Pristane (2,6,10,14-
tetramethylpentadecane) is another naturally occurring saturated
hydrocarbon oil, which has been tested for its adjuvanticity. It is
an isoprenoid alkane that is derived primarily from the metabo-
lism of phytol. However, like CFA, pristane can cause a number
of adverse side effects including development of plasmacytomas
and generation of autoimmune conditions such as lupus and
arthritis (Holmdahl et al., 2001). Currently, many other adjuvants
have been described with variable safety and immunostimulation
records. However, despite these efforts, aluminum salt/gel-based
(alum) adjuvants remain the only standard versatile adjuvant
licensed for human use in the United States. Even alum has a
number of drawbacks. Alum cannot induce a T helper type 1
(Th1) cell-mediated immune response that is important in ﬁght-
ing certain viruses, bacteria, and parasites (Brewer et al., 1999). It
has also been implicated in dementia, a loss of brain function that
occurs with certain diseases (Marchkesbery et al., 1981). There-
fore, the goal of our laboratory has been to develop safer and more
broadly applicable adjuvants from natural compounds like ter-
penoids that meet all the hallmarks of an ideal adjuvant outlined
in Figure 1.
Our studies revealed phytol to be a potent adjuvant but not
without side effects. Adverse effects induced by phytol include
splenomegaly, hepatotoxicity, and tumor promotion in rodents
(Kagoura et al., 1999). Prior studies have also linked phytol to Ref-
sum disease, an autosomal recessive disorder that results from the
accumulation of unmetabolizable phytanic acid in tissues (Baxter,
1968). In order to overcome known and hitherto unknown short-
comings of phytol, we developed novel adjuvants by introducing
chemical modiﬁcations to phytol; the goal was to improve their
safety and enhance their adjuvanticity. Phytanol, which we named
PHIS-01 (phytol-based immunostimulants 01), was obtained by
hydrogenation of phytol. This modiﬁcation not only reduced toxi-
city but also enhanced adjuvanticity. Indeed,PHIS-01provedmore
potent and less toxic than phytol. This observation led us to ques-
tion: (1) the importance of the phytyl moiety and (2) the nature
of functional groups in adjuvanticity of synthetic phytol deriva-
tives. These issues paved the way to the generation of a number of
novel phytol derivatives (as shown in Figure 2),where the terminal
-OH is modiﬁed by amination, producing phytanyl amine (PHIS-
02), mannosylation producing phytanyl mannose (PHIS-03) and
halogenations producing phytanyl bromide, phytanyl chloride,
phytanyl ﬂuoride, and phytanyl iodide. All of these derivatives
have three chiral centers and are racemic at all three. Further
modiﬁcations for better adjuvanticity are currently in progress.
Our objective has been to understand how the various side groups
affect the adjuvanticity, the dosage required for adjuvanticity vis-
à-vis toxicity, effects on microenvironments surrounding innate
and acquired immunity and the amplitude of speciﬁc immune
responses. The importance of the phytyl moiety in adjuvanticity
was demonstrated by assessing the booster effects of phytane rela-
tive to phytol derivatives and some commercial adjuvants (Ghosh,
2012).
RATIONALE BEHIND SPECIFIC CHEMICAL MODIFICATIONS
Chemical modiﬁcation of adjuvants to improve their effectiveness
is not new, but only limited reports have appeared. The objective
of these modiﬁcations has generally been to produce effective and
safer products and to understand structural intricacies required
for adjuvanticity. For example, bacterial lipopolysaccharide (LPS)
is toxic, but it has excellent ability to mobilize innate immunity
by virtue of Toll-like and other receptors, and promote matura-
tion of dendritic cells (Yoshino et al., 2000). However, its modiﬁed
version monophosphoryl lipid A (MPL) is less toxic but a bet-
ter adjuvant (Salkowski et al., 1997; Thompson et al., 2005). In
Quillaja saponin adjuvant, introduction of an aldehyde group
promotes a Th1 type cellular response against virus or cancer
(Rhodes et al., 1995; Marciani et al., 2000; Thompson et al., 2005)
whereas the deacylated saponin, lacking the aldehyde functional
Frontiers in Immunology | Immunotherapies and Vaccines March 2012 | Volume 3 | Article 49 | 2
Chowdhury and Ghosh Phytol-derived novel isoprenoid immunostimulants
FIGURE 1 | Schematic diagram showing eight hallmark features of an ideal adjuvant.
group, favors a Th2-mediated antibody response (Marciani et al.,
2001).
We hypothesized that the polar terminal moiety has a profound
effect on the physico-chemical properties and therefore on the
adjuvanticity of a compound. The physico-chemical properties
necessary for immunomodulation by oil-in-water adjuvants are
not fully understood. These emulsions function in many capac-
ities from membrane anchoring to cell signaling. PHIS-01 has a
-OH terminal group that is negatively charged. Halogenations of
the terminal group increase its electronegativity, making the mol-
ecule more hydrophilic. Hydrophilicity possibly plays a role in the
uptake and retention of the antigen by immune cells. Mannosyla-
tion further increases the electronegativity due to the presence of
multiple OH groups in PHIS-03. Amination of phytol was per-
formed to analyze the effects of a positively charged terminal
residue (-NH2) on the adjuvanticity of compounds. Differences
in the modes of actions of these various adjuvants in terms of
T cell bias (modiﬁcation of the polar terminus of PHIS-01 with
a hydrophilic mannose moiety (PHIS-03) favors T helper type
2 rather than the T helper type 1 response induced by PHIS-
01; Aachoui et al., 2011b). These ﬁndings support the fact that
the nature of the polar end group in these compounds is an
important modiﬁer of adjuvanticity. An exchange of the simple
alcohol or amine moiety with a mannosyl group can markedly
alter the type of immune response elicited. Additional mannosy-
lations may have entirely different effects on the phytyl moiety
in terms of solubility and adjuvanticity; this aspect is currently
being addressed. Another question addressed in our studies was
how the polar terminus affects adjuvanticity in terms of host
microenvironment (cytokine/chemokine milieu) and safety pro-
ﬁle. Among the phytol derivatives, PHIS-01 and the halogenated
phytanyl compounds were found to have no toxicity even at
high doses. PHIS-01 is highly effective over a wider range of
concentrations (4–44mg/mouse). PHIS-02 functions at a much
lower concentration (2.5mg/mouse), and PHIS-03 works effec-
tively at an intermediate dose (5mg/mouse). However both PHIS-
02 and PHIS-03 showed toxicity at higher doses (LD50 values for
these compounds are 5 and 10mg/mouse respectively; Aachoui
et al., 2011a). The fact that some phytol derivatives are effective
adjuvants at relatively lower doses should be good news since
host exposure to the chemicals is minimal. The study of adju-
vanticity in mouse models is convenient and important, because
it permits the evaluation of not only histopathological toxic-
ity and adjuvanticity but also tumorigenicity. In this context,
the phytol derivatives mentioned above, have no tumorigenic
properties.
COMPARATIVE EFFECTIVENESS OF PHYTOL ISOPRENOIDS
AND SOME COMMERCIAL ADJUVANTS
From Table 1, it is clear that numerous challenges exist in the
development of safe and versatile immunostimulants. Some of
these challenges include the ability to minimize inﬂammation and
induce both robust immune response and long-term memory. It
is highly unlikely that a single immunoadjuvant will fulﬁll all that
is needed for a non-toxic, broad and long lasting immunity. Com-
pounds that have been proven safe, like alum, can be effective in
eliciting only one arm of the immune response, limiting their use
as versatile adjuvants. The art of making vaccines will undoubt-
edly be simpler with the understanding of the structural basis of
adjuvanticity, which will eliminate the shroud of empiricism that
currently exists in their selection. Moreover, this will pave the way
to the generationof cocktail adjuvants for broader applications.An
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FIGURE 2 | Structures and chemical modifications of phytol-derived immunostimulants.
overview of the modes of actions of some commercially available
immunostimulants and the phytol derivatives is given below in
Table 2.
MODES OF ACTION OF PHYTOL-DERIVED ADJUVANTS
The adjuvanticity of compounds as listed in Table 2, is shaped
not only by their molecular nature but also by the nature of
the associated antigen (vaccine; Staats and Ennis, 1999), routes
of administration (Petrovsky and Aguilar, 2004), and the verte-
brate hosts (Casadevall and Pirofski, 1998). The efﬁciency of an
adjuvant can be ascertained by its potential to boost immune
responses against a variety of antigens. This is because the
offending agents are not always pathogens. The threats may
come from toxins, cancers, pollens, and many soluble and insol-
uble particulates. The list and nature of offending agents is
continuously expanding and even includes addictive compounds
such as cocaine. Even though vaccines have greatly impacted
global health, fears persist about their potential role in the devel-
opment of autoimmune and various adverse symptoms. Hence,
vaccine components like immunogens and adjuvants require
critical evaluation not only in healthy subjects, but also in those
who are genetically averse to vaccine constituents, or in other
words, populations representing varying degrees of immune
competence.
Similarly, the efﬁcacy of adjuvants can be markedly different
depending on the routes of administration. For example, alum is
usually more effective when administered through intradermal or
subcutaneous routes than through intramuscular routes.However,
due to local toxicity, alum is generally only used intramuscularly
(Butler et al., 1969; Straw et al., 1985).
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Table 1 | Adjuvanticity of phytol and its derivatives compared to commercially available adjuvants.
Hallmark features Alum Squalene (MF59) CFA/IFA Saponins (QS-21) Phytol Phytol derivatives
Safety (Petrovsky
and Aguilar, 2004)
(Asa et al.,
2000)
(Oscherwitz
et al., 2006)
(Sun et al.,
2009)
(Baxter, 1968) (Aachoui et al.,
2011a)
Stability (Maa et al.,
2002)
(Granoff et al.,
1997)
(Dvorak and
Dvorak, 1974)
(Sun et al.,
2009)
(Lim et al.,
2006a)
(Aachoui et al.,
2011a)
Bioavailability (Petrovsky
and Aguilar, 2004)
(Stills, 2005) (Stills, 2005) (Song and Hu,
2009)
(Lim et al.,
2006a)
(Aachoui et al.,
2011a)
Cost–effectiveness (Petrovsky
and Aguilar, 2004)
(Ott et al.,
2002)
(Lévesque
et al., 2007)
(Skene and
Sutton, 2006)
(Lim et al.,
2006a)
(Aachoui et al.,
2011a)
Antibody response (Gupta et al.,
1993)
(Granoff et al.,
1997)
(Cribbs et al.,
2003)
(Estrada et al.,
1998)
(Lim et al.,
2006a)
(Aachoui et al.,
2011a)
T helper cell activation (Brewer et al.,
1999)
(Baudner
et al., 2009)
(Cribbs et al.,
2003)
(Rajput et al.,
2007)
(Lim et al.,
2006a)
(Aachoui et al.,
2011b)
Immunological memory (Krishnan
et al., 2000)
(Banzhoff
et al., 2009)
(Yip et al.,
1999)
(Mastelic et al.,
2010)
(Lim et al.,
2006a)
(Aachoui et al.,
2011b)
CTL induction (Lindblad,
1995)
(Heinemann
et al., 2008)
(Yip et al.,
1999)
(Sun et al.,
2009)
(Lim et al.,
2006a)
(Lim et al.,
2006a)
Promotion of crosstalk (Didierlaurent
et al., 2009)
(Seubert
et al., 2008)
(Lee et al.,
2011)
(Kensil et al.,
2006)
(Lim et al.,
2006a)
(Aachoui et al.,
2011b)
Prevention of
autoimmunity
(Geiera et al.,
2009)
(Montagnani
et al., 2011)
(Matthys
et al., 1999)
(Sparg et al.,
2004)
(Lim and
Ghosh, 2003)
(Lim and Ghosh,
2003)
Non-pathological
inﬂammatory response
(Li et al.,
2008)
(Mosca et al.,
2008)
(Raghavendra
et al., 2004)
(Stills, 2005) (Kagoura
et al., 1999)
(Aachoui et al.,
2011b)
Legend: Inadequate feature; Effective feature
The adjuvanticity of the phytol-derived compounds was
assessed in the context of the following biological effects:
i. Minimal effective doses to overcome cumulative toxic effects,
if any
ii. Amplitude and quality (isotype) of speciﬁc antibody response
iii. Crosstalk between innate and acquired immunity and modu-
lation of cytokine chemokine microenvironments
iv. Nature of inﬂammatory responses
v. Generation of long-term immunological memory
vi. Prevention of autoimmune responses
EVALUATION OF IN VIVO TOXICITY
Asmentioned earlier, the phytol derivatives are non-toxic and have
no cumulative debilitating effects like development of plasmacy-
tomas or arthritis (Aachoui et al., 2011a), as observed with some
commercial adjuvants (Kagoura et al., 1999; Matthys et al., 1999).
INDUCTION OF SPECIFIC HUMORAL IMMUNE RESPONSE
Keeping in mind the knowledge about the empiricism in the
choice of adjuvants,we tested the phytol-derived adjuvants inmice
(BALB/c and C57BL/6) against a variety of antigens including:
(1) a standard protein antigen (Ovalbumin), (2) a hapten-protein
conjugate (Phthalate-Keyhole Limpet Hemocyanin), (3) a Gram-
positive bacterial pathogen (Staphylococcus aureus), (4) a Gram-
negative bacterial pathogen (Escherichia coli), and (5) Tumor anti-
gens (2C3, A20 B-lymphomas and EG7-OVA, T-lymphoma). We
also tested efﬁcacy of some phytol adjuvants admixed with protein
antigens in New Zealand white rabbits. The efﬁcacy of the phytol
derivatives was compared to a number of different commercially
available adjuvants like alum, complete, and in CFAs and squalene
in different sets of experiments. Our ﬁndings reveal that the phytol
derivatives consistently evoke high titer antibody response against
the various antigens, promote efﬁcient class switching and are
better than the commercial adjuvants tested (Lim et al., 2006a,b;
Li, 2009; Aachoui, 2011).
The robustness of the antibody response induced in the various
adjuvant-treated groups was evaluated in terms of isotype switch-
ing, since it is as away to ascertain the involvement of Thelper cells.
Our results showed that the phytol-derived adjuvants induced all
IgG sub classes, in much the same way as IFA, the most potent
commercial adjuvant known. The control group with no adjuvant
yielded only IgG1 type antibody, while all adjuvant-treated groups
induced IgG2a, IgG2b, and IgG3 in addition to IgG1. Elicitation
of these various IgG subclasses testiﬁed the promotion of T helper
cell polarization by the test adjuvants (Aachoui et al., 2011a,b). The
phytol derivatives were also found to induce long-term immuno-
logicalmemory irrespective of the nature of the antigen (Lim et al.,
2006b).
In order to investigate the efﬁcacy of the phytol compounds
in inducing antigen-speciﬁc cytotoxic T-lymphocytes (CTL),
two different tumor models, namely E.G7-OVA and 2C3 were
used in C57BL/6 and BALB/c mice respectively. The results
showed that phytol derivatives in vaccine formulations, unlike
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Table 2 | Comparison of the modes of action of phytol derivatives with other common adjuvants.
Immunostimulants Modes of actions References
Alum InductionTh2-type immune response characterized by IgG1 isotype antibodies Lindblad (1995)
Danger model*: induction of necrosis and release of uric acid Allan (2008)
Activation of Nlrp3 inﬂammasome leading to the release of pro-inﬂammatory cytokines Li et al. (2008)
Clonal expansion of antigen-speciﬁc T cells and B cell priming Smith et al. (2004)
Formation of antigen depot leading to its slow release Blagowechensky (1938)
Direct interaction with dendritic cell surface lipids Mbow et al. (2011)
MF59 Induction of both Th1 andTh2-type immune responses Traquina et al. (1996)
Recruitment and activation of APCs Banzhoff et al. (2008)
Recruitment of innate immune cells like monocytes and granulocytes Seubert et al. (2008)
Freund’s adjuvants Induction of both Th1 (CFA#) andTh2-type immune responses (IFA§) Billiau and Matthys (2001)
Stimulation of localized inﬂammations Matthys et al. (1999)
Mycobacterium in CFA act as PAMPs+ and can activate Toll-like receptors Lim (2003)
Recruitment and activation of APCs McInerney et al. (1991)
Saponins Induction of CTL response (both Th1 andTh2 cytokines) Oda et al. (2000)
Promotion of antigen presentation to APCs? Cox et al. (1998)
Phytol derivatives Induction of both Th1 andTh2 responses Aachoui et al. (2011b)
Induction of CTL response Lim et al. (2006a)
Activation of the Nlrp3¶ inﬂammasome leading to the release of pro-inﬂammatory cytokines Aachoui et al. (2011b)
*Danger signal hypothesis (Kono and Rock, 2008).
+PAMPS, pathogen associated molecular patterns (Kono and Rock, 2008).
¶Nlrp3, Nod-like receptor protein 3.
#CFA, Complete Freund’s adjuvant.
§IFA, Incomplete Freund’s adjuvant.
?APCs, Antigen-presenting cells.
Alum, could elicit tumor-speciﬁc cell-mediated effector activity.
Phytol and PHIS-01 were also found to signiﬁcantly augment
idiotype-speciﬁc CTL responses (Lim et al., 2006a).
These results clearly established that the phytol derivatives were
not only potent elicitors of the humoral immune response,but also
were effective against diverse groups of antigens. In this regard, the
phytol derivatives are better immunostimulants than alum, which
is ineffective against several antigens and fail to induce antitumor
CTL responses.
The efﬁcacy of phytol derivatives against viral antigens has not
been tested yet,but this deﬁnitely remains an area of future interest.
Since some of the phytol-derived compounds have shown signif-
icant CTL induction, we believe that they could be useful in the
development of viral vaccines.
MOBILIZATION OF BIO-RESPONSE MODIFIERS AND INDUCTION OF
INFLAMMATORY RESPONSES
The importance of chemical bonds and functional moieties in
shaping the adjuvanticity of terpenoids, like phytol derivatives,
can be discerned from the ability of these compounds to polarize
the immune system by mobilizing myriad bio-response modiﬁers.
Cytokines and chemokines are bio-response modiﬁers, because
they determine the immune microenvironment by orchestrating
the recruitment and interaction of cells belonging to both innate
and acquired immunity. Cytokine/chemokine arrays performed
for PHIS-01, PHIS-02, and PHIS-03 revealed that PHIS-01 and
PHIS-03 triggered a polarization of T cell response that developed
24 h post-injection (Aachoui et al., 2011b). PHIS-01 induced a
Th1 response while PHIS-03 promoted a Th2 response (Aachoui
et al., 2011b). PHIS-02 had a proﬁle similar to that of PHIS-01.
This type of T-lymphocyte polarization can have great implica-
tions in thedevelopment of successful cocktail immunostimulants.
Among the phytol derivatives tested, PHIS-01 was the most potent
in evoking T cell activating chemokines like RANTES, TCA-3, and
cytokines like IL-12 and IL-4.
Expression of chemokines like KC (CXCL1, murine equivalent
of IL-8), LIX (CXCL5), and MCP-1 (CCL2) was high in all adju-
vanted groups including alum, although the effect was much more
pronounced with the phytol-based immunostimulants. Surges in
the expression of these chemokines reﬂect the mobilization of
neutrophils, eosinophils, and monocytes. The phytol derivatives,
unlike alum,also induced the secretionof the growth factorG-CSF.
In contrast to all other groups, PHIS-01 showed enhanced expres-
sion of chemokines like SDF-1, MIG, Fas ligand, and Fractalkine.
These results proved PHIS-01 to be the most effective in eliciting a
full-bodied immune response by activating cells of both the innate
and acquired immunity.
Both the adjuvant and the antigen shape the immune microen-
vironment. In order to understand how the dynamics of the
cytokine microenvironment change in the presence of an antigen,
we assessed the cytokinemilieu at peritoneal sites 24 h after admin-
istration of soluble protein antigensKLHandOVAwith orwithout
alum or PHIS-01, PHIS-02, and PHIS-03. Our results showed that
when the adjuvants were mixed with the antigens KLH and OVA, a
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large pool of cytokines and chemokines (notably, BLC, Eotaxin-2,
LIX, MCP-1, MIP-1γ, TCA-3, M-CSF, IL-4, IL-12p40p70, IL-1α,
sTNFRI, sTNFRII) was induced, thereby further impacting the
cytokine/chemokine microenvironment (Aachoui et al., 2011b).
However, what percentage of the eventual cytokine/chemokine
microenvironment, is contributed by the antigen or the adjuvant
in the mix, remains unclear. Both antigens and adjuvants have
their respective molecular signatures, which may largely be differ-
ent from themolecular signatureswhen the antigens and adjuvants
are emulsiﬁed together. The host immune environment is the net
outcome from the combined contributions of both adjuvants and
immunogens.
The cytokine milieu plays a signiﬁcant role in setting the
pace and overcoming the barriers of CD4+CD25+regulatory T
cells (T-regs; Medzhitov and Pasare, 2003; Pasare and Medzhi-
tov, 2004). The efﬁcacy of standard and experimental adjuvants
therefore needs to be assessed in terms of their ability to lower
the impediments posed by T-regs and other immunoregulatory
mechanisms. This is critical, particularly in order to provoke anti-
tumor immunity. It is not clear whether overcoming barriers due
to immune tolerance to tumor requires kinds of adjuvants that
induce inﬂammatory response. Our experience with phytol deriv-
atives, particularly PHIS-01, suggests that inﬂammation is not a
prerequisite in overcoming immune refractoriness of the host.
Our experiments revealed that the phytol derivatives function
by exerting apoptotic/necrotic effects on target cells. However,
these apoptotic/necrotic effects induced by the phytol deriva-
tives did not persist as happens with Freund’s adjuvants (Aachoui
et al., 2011a). We therefore hypothesized that the efﬁciency of
the phytol-based adjuvants depended on their ability to induce
non-pathological inﬂammatory reactions, elaborating cytokines
and chemokines capable of the recruitment and activation of
APCs. In order to test this hypothesis, we analyzed the expres-
sion patterns of 84 genes associated with various inﬂammasome
pathways. Our results showed that like alum, the phytol-based
immunostimulants boost the expression of the NLRP gene family,
speciﬁcally NLRP3 and other inﬂammasome complexes (Aachoui
et al., 2011b). PHIS-01 in particular, activated the genes of the
NLRP3 Inﬂammasome, suggesting a mode of action similar to
that of alum even though the latter does not induce CTL response
(Lindblad, 1995).
Our cytokine/chemokine and inﬂammasome array data
together indicate that the phytol compounds initiate and acti-
vate both the innate and acquired immunity by cell recruitment,
increased endocytosis in monocytes, stimulation of monocyte dif-
ferentiation into macrophage or DC, and activation of T cells.
PHIS-01 is more potent than PHIS-03 in the induction of mul-
tiple Nod-like receptors, cytokines/chemokines and downstream
signaling molecules. This ﬁnding may account for the ability of
PHIS-01 to activate both the Th1 and Th2 responses in contrast
to PHIS-03, which only activates a Th2 response. From our stud-
ies, it is apparent that innate immunity plays an important role in
the adjuvanticity of phytol derivatives. Both PHIS-01 and PHIS-
03 activated a cluster of molecules such as IL-1α, Timp-1, Cﬂar,
Bir3, and XIAP, that function as tissue injury response molecules
or for blocking of apoptosis. PHIS-01 was a very potent inducer
of these genes, which implied a higher apoptotic/necrotic activity;
as a result of which, there could be signiﬁcant release of danger
signal molecules from the surrounding tissues leading to the acti-
vation of innate immunity. Based on the information gathered
from our cytokine/chemokine and inﬂammasome arrays, we pre-
dicted a putative signaling pathway (Figure 3) that could delineate
the mode of action of phytol-based immunostimulants.
The study of adjuvants and their efﬁcacy or versatility leaves
us with the following questions: (1) Can adjuvants overcome
immunological anergy by triggering inﬂammasomes (that eventu-
ally lead to activation of NLRP or IL-1)? (2) Do speciﬁc immunity
and its robustness depend on non-pathological inﬂammation
initiated by adjuvants?
PREVENTION OF AUTOIMMUNE RESPONSES
The success of an immunostimulant depends not only on its abil-
ity to elicit a robust immune response, but also its safety and wide
applicability. A major concern that persists about immunostimu-
lants is their potential role in autoimmune reactions. Evaluation
of immunostimulants in autoimmune-prone animal models is
therefore important in vaccine development. Our previous stud-
ies have shown that phthalate, as a conjugate or as DEHP (diethyl
hexyl phthalate, a plasticizer), can induce cross reactive anti-
DNA antibody response and promote lupus-like syndromes in
NZB/WF1 mice (Lim and Ghosh, 2003, 2004). This ability of
phthalate to induce both anti-phthalate and cross reactive anti-
DNA antibodies was, therefore, utilized to assess the efﬁcacy
and safety of the phytol derivatives (PHIS-01, PHIS-03) relative
to alum. We studied phthalate-speciﬁc antibody response, anti-
DNA response, and other parameters of autoimmune disorder.
We also assessed antibody isotype and cytokine/chemokine proﬁle
induced.
Pristane, an isoprenoid adjuvant like the phytol derivatives, has
been shown to promote lupus-like syndromes and pathological
nephritis in both autoimmune-prone and non-susceptible mouse
strains after a single intra-peritoneal injection. However, in spite
of their structural similarities to pristane, the phytol derivatives
did not induce any adverse autoimmune symptoms. Additionally,
squalene, a triterpene (similar to the diterpene phytol derivatives),
and Freunds’ adjuvants (CFA/IFA) are also known to provoke
lupus-like syndromes in non-autoimmune-prone BALB/c mice
(Satoh et al., 2003).
An imbalance between the Th1 and Th2 cytokines is considered
a hallmark of lupus. In a previous study, it has been shown that
hydrocarbon oil adjuvants like pristane can induce an overpro-
duction of Th1 polarizing cytokines like INF-γ (Peng et al., 1997).
This and high levels of IL-6 and TNF-α can aggravate lupus-like
diseases in rodents. NZB/WF1 mice immunized with phthalate-
KLH alone or with adjuvants induced moderate expressions of
bothTh1 (IFN-γ, IL-12) andTh2 (IL-3, -4, -10, and -13) cytokines,
and low but detectable levels of pro-inﬂammatory cytokines (IL-1,
IL-6, IL-17, TNF-α). All adjuvant-treated groups registered high
levels of anti-inﬂammatory cytokines TNFRII, TNFRI, TIMP-1.
Interestingly, the Th1 and Th2 responses generated by different
adjuvants was directedmore toward phthalate as evident by induc-
tion of the IgG subclass, whereas the cross reactive anti-ds DNA
response was mostly IgM with little IgG subclass switching, indi-
catingno afﬁnitymaturationormemory induction,characteristics
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FIGURE 3 | Possible signaling pathway activated by the
phytol-based immunostimulant PHIS-01. PHIS-01 induces IFN-γ,
leading to the activation of the transcription factor IRF-1 that transcribes
genes resulting in Th1 polarization, cytotoxic T-lymphocyte
development, induction of apoptosis and also possibly the activation of
NK cells. PHIS-01 induced apoptosis/necrosis can generate DAMPS
leading to the activation of the Nlrp3 inﬂammasome and production of
inﬂammatory cytokines. MyD88 and p38 mediated activation of NF-KB
is probably induced by PHIS-01 indirectly via the activation of Toll-like or
Nod-like receptors.
of Thelper activity on antigen-speciﬁcB cells (Ghosh andAachoui,
2011).
DISCUSSION
The overall objective of this review was to provide comparative
pictures of both commercial and phytol-based synthetic adju-
vants. Our ﬁndings support the contention that phytol-derived
adjuvants are safe and efﬁcacious immunostimulants. This con-
clusion can be drawn on the basis of their ability to promote
effective humoral response, stimulate T cell proliferation with-
out exhibiting any adverse autoimmune anti-DNA response in
resistant and susceptible mice strains. Future studies with selective
chemical modiﬁcations of simple diterpenoids like phytol, fol-
lowed by assessment of adjuvanticity, may unlock key structural
features necessary for effectiveness of such immunostimulants.
The rewarding aspect of adjuvant research is that it not only
paves the way to improving current technology for vaccine devel-
opment, but also addresses basic questions relating to immuno-
logical memory. One current thought is that some fragments
of immunogenic substances are retained by APCs in order to
sustain immune memory in B and T cells; these APCs possibly up-
regulate BCL2, BCL-XL, and similar anti-apoptotic transcription
factors. It is not clear how adjuvants augment immunogenic-
ity and efﬁcacy of vaccines. It is possible that adjuvants directly
work on anti-apoptotic molecules or sustain a chronic inﬂamma-
tory cytokine milieu favorable for retention of memory cells. It
may also be possible to structurally modify and design adjuvants
that selectively favor the induction of speciﬁc classes of antibody
molecules, such as non-complement ﬁxing IgG4. Using phytol-
derived diterpenoids we hope to address some of these questions
in future.
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